Applying the IWG Research Criteria in Clinical Practice. Feasibility and Ethical Issues

Medical Clinics of North America

Volumn 97, Issue 3, 2013, Pages 477-484

  Molinuevo, José L ^a,b   Rami, Lorena ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Alzheimer disease; Bioethics; Biomarkers; Diagnosis

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLUTEMETAMOL F 18; TAU PROTEIN;

ALZHEIMER DISEASE; AMNESIA; CEREBROSPINAL FLUID; CLINICAL PRACTICE; COGNITIVE DEFECT; EARLY DIAGNOSIS; EPISODIC MEMORY; FEASIBILITY STUDY; GRAY MATTER; HUMAN; INTERNATIONAL WORKING GROUP CRITERIA; MEDICAL ETHICS; MIDDLE FRONTAL GYRUS; MILD COGNITIVE IMPAIRMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARAHIPPOCAMPAL GYRUS; PATIENT ADVOCACY; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SELF CONCEPT; SENSITIVITY AND SENSIBILITY; SENSITIVITY AND SPECIFICITY; UNCUS; VALIDITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; BRAIN; ETHICS, MEDICAL; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; STATISTICS AS TOPIC; TAU PROTEINS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84877052133     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.12.018     Document Type: Review

References (27)

1. Alzheimer's Disease International World Alzheimer Report 2011: The benefits of early diagnosis and intervention 2011, Prof Martin Prince, Dr Renata Bryce and Dr Cleusa Ferri, Institute of Psychiatry, King's College London, UK, Alzheimer's Disease International (ADI).
2. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
3. Ballard C., Gauthier S., Corbett A., et al. Alzheimer's disease. Lancet 2011, 377:1019-1031.
4. Buckhave P., Minthon L., Zetterberg H., et al. Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Arch Gen Psychiatry 2012, 69:98-106.
5. Dubois B., Feldman H.H., Jacova C., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
6. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendation from the national institute of aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
7. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Alzheimer's Disease Neuroimaging Initiative, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413.
8. Clark C.M., Pontecorvo M.J., Beach T.G., et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012, 11:669-678.
9. Antonell A., Fortea J., Rami L., et al. Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 2011, 118:259-262.
10. Pike K.E., Ellis K.A., Villemagne V.L., et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 2011, 49:2384-2390.
11. Engelborghs S., De Vreese K., Van de Casteele T., et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008, 29:1143-1159.
12. Le Bastard N., Martin J.J., Vanmechelen E., et al. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging 2010, 31:1867-1876.
13. Leinonen V., Alafuzoff I., Aalto S., et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008, 65:1304-1309.
14. Wolk D.A., Grachev I.D., Buckley C., et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011, 68:1398-1403.
15. Swerdlow R.H., Jicha G.A. Alzheimer disease: can the exam predict the pathology?. Neurology 2012, 78:374-375.
16. Landau S.M., Harvey D., Madison C.M., et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238.
17. Tounsi H., Deweer B., Ergis A.M., et al. Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease. Alzheimer Dis Assoc Disord 1999, 13:38-46.
18. Sarazin M., Berr C., De Rotrou J., et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 2007, 69:1859-1867.
19. Wagner M., Wolf S., Reischies F.M., et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 2012, 78:379-386.
20. Beach T.G., Monsell S.E., Phillips L.E., et al. Accuracy of the clinical diagnosis of alzheimer disease at national institute on aging alzheimer disease centers. J Neuropathol Exp Neurol 2012, 71:266-273.
21. Bouwman F.H., Verwey N.A., Klein M., et al. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 2010, 30:1-7.
22. Galluzzi S., Geroldi C., Ghidoni R., Translational Outpatient Memory Clinic Working Group, et al. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 2010, 257:2004-2014.
23. Rami L., Solé-Padullés C., Fortea J., et al. Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. Int J Geriatr Psychiatry 2012, 27:127-134.
24. Black J.S. Telling the truth: should persons with Alzheimer's disease be told their diagnosis?. Alzheimer's Disease International Global Perspective 1995, 6:10-11.
25. Alzheimer's Association website. Diagnostic disclosure. Alzheimer's Association. 2011. Available at: Accessed June 15, 2011. http://www.alz.org/professionals_and_researchers_diagnostic_disclosure.asp.
26. Beauchamp T.L., Childress J. Principles of biomedical ethics 2001, NY Oxford University Press, New York, Chapter 3.
27. Ezekiel E., Wendler D., Grady C. What makes clinical research ethical?. JAMA 2000, 283:2701-2711.